BioMark Diagnostics Inc.
BUX
CNSX
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Net Income | -1.39M | -1.39M | -1.45M | -1.20M | -1.06M |
Total Depreciation and Amortization | 284.70K | 201.40K | 232.40K | 257.30K | 291.60K |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | 311.10K | 288.80K | 290.90K | 231.30K | 102.60K |
Change in Net Operating Assets | 13.40K | 271.00K | 61.10K | -61.50K | -62.40K |
Cash from Operations | -780.70K | -624.90K | -861.50K | -774.50K | -726.00K |
Capital Expenditure | -2.50K | -2.70K | -4.30K | -5.00K | -3.20K |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -- | -- | -- | -- | -- |
Cash from Investing | -2.50K | -2.70K | -4.30K | -5.00K | -3.20K |
Total Debt Issued | 378.20K | 378.20K | 357.20K | 357.20K | 357.20K |
Total Debt Repaid | -567.80K | -773.70K | -1.07M | -1.20M | -1.18M |
Issuance of Common Stock | 3.61M | 1.03M | 1.76M | 1.87M | 1.89M |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -- | -- | -- | -- |
Cash from Financing | 2.40M | 460.70K | 766.60K | 753.60K | 791.50K |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | 1.62M | -166.80K | -99.00K | -25.90K | 62.10K |